Visual and Auditory Neurotoxicity in Patients Receiving Subcutaneous Deferoxamine Infusions

New England Journal of Medicine

Volumn 314, Issue 14, 1986, Pages 869-873

  Olivieri, Nancy F ^a   Buncic, J Raymond ^a   Chew, Emily ^a   Gallant, Tsvi ^a   Harrison, Robert V ^a   Keenan, Nancy ^a   Logan, William ^a   Mitchell, David ^a   Ricci, Geri ^a   Skarf, Barry ^a   Taylor, Margot ^a   Freedman, Melvin H ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

COTRIMOXAZOLE; DEFEROXAMINE; PENICILLIN G; SULFAMETHOXAZOLE; TRIMETHOPRIM; VISUAL PIGMENT;

ADVERSE DRUG REACTION; ARTICLE; AUDITORY SYSTEM; BLACKFAN DIAMOND ANEMIA; BLOOD AND HEMOPOIETIC SYSTEM; CENTRAL NERVOUS SYSTEM; DRUG DOSE; DRUG THERAPY; EYE TOXICITY; HEARING IMPAIRMENT; HUMAN; INTOXICATION; MAJOR CLINICAL STUDY; NERVOUS SYSTEM; NEUROTOXICITY; OPTIC NERVE DISEASE; OTOTOXICITY; PERCEPTION DEAFNESS; PERIPHERAL NERVOUS SYSTEM; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; THALASSEMIA; THALASSEMIA MAJOR; THERAPY; VISUAL IMPAIRMENT; VISUAL SYSTEM;

EID: 0022628511     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM198604033141402     Document Type: Article

References (11)

1. Sephton-Smith R. Iron excretion in thalassaemia major after administration of chelating agents. Br Med J 1962; 2: 1577–80.
2. Weatherall DJ, Clegg JB. The thalassaemia syndromes. London: Blackwell, 1981:704–5.
3. Arden GB, Wonke B, Kennedy C, Huehns ER. Ocular changes in patients undergoing long-term desferrioxamine treatment. Br J Ophthalmol 1984; 68: 873–7.
4. De Virgiliis S, Argiolu F, Sanna G, et al. Auditory involvement in thalassemia major. Acta Haematol (Basel) 1979; 61: 209–15.
5. Bloomfield SE, Markenson AL, Miller DR, Peterson CM. Lens opacities in thalassemia. J Pediatr Ophthalmol Strabismus 1978; 15: 154–6.
6. Davies SC, Marcus RE, Hungerford JL, Miller MH, Arden GB, Huehns ER. Ocular toxicity of high-dose intravenous desferrioxamine. Lancet 1983; 2: 181–4.
7. Lakhanpal V, Schocket SS, Jiji R. Deferoxamine (Desferal)-induced toxic retinal pigmentary degeneration and presumed optic neuropathy. Ophthalmology (Rochester) 1984; 91: 443–51.
8. Simon P, Ang KS, Meyrier A, Allain P, Mauras Y. Desferrioxamine, ocular toxicity, and trace metals. Lancet 1983; 2: 512–3.
9. Rubinstein M, Dupont P, Doppee J-P, Dehon C, Ducobu J, Hainaut J. Ocular toxicity of desferrioxamine. Lancet 1985; 1: 817–8.
10. Borgna-Pignatti C, De Stefano P, Broglia AM. Visual loss in patient on high-dose subcutaneous desferrioxamine. Lancet 1984; 1: 681.
11. Lederman HM, Cohen A, Lee JWW, Freedman MH, Gelfand EW. Deferoxamine: a reversible S-phase inhibitor of human lymphocyte proliferation. Blood 1984; 64: 748–53.